Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials

Michael J. BurkeMedical College of Wisconsin and Children’s Hospital of Wisconsin, Milwaukee, WI, USA; Correspondence[email protected]

Meenakshi DevidasDepartment of Biostatistics, University of Florida, Gainesville, FL, USA;

Kelly MaloneySchool of Medicine and Children’s Hospital of Colorado, University of Colorado, Aurora, CO, USA;

Anne AngiolilloChildren’s National Medical Center, Washington, DC, USA;

Reuven SchoreChildren’s National Medical Center, Washington, DC, USA;

Kimberly DunsmoreUniversity of Virginia Children’s Hospital, Charlottesville, VA, USA;

Eric LarsenMaine Children’s Cancer Program, Scarborough, ME, USA;

Len A. Mattano Jr.HARP Pharma Consulting, Mystic, CT, USA;

Wanda SalzerUS Army Medical Research and Materiel Command, Fort Detrick, MD, USA;

Stuart S. WinterHealth Sciences Center, University of New Mexico, Albuquerque, NM, USA;

William CarrollLaura and Issac Perlmutter Cancer Center at NYU, New York, NY, USA;

Naomi J. WinickSouthwestern Simmons Cancer Center, University of Texas, Dallas, TX, USA;

Mignon L. LohBenioff Children’s Hospital, University of California San Francisco, San Francisco, CA, USA;

Elizabeth RaetzDepartment of Pediatrics, University of Utah, Salt Lake City, UT, USA;

Stephen P. HungerChildren’s Hospital of Philadelphia, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;

Archie BleyerDepartment of Pediatrics, Oregon Health and Science University, Portland, OR, USA

Your download is now in progress and you may close this window